In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon’s McCoy Reveals Plan Of Attack For Stabilization, Growth

This article was originally published in The Rose Sheet

Executive Summary

At the Consumer Analyst Group of New York conference Feb. 21, Avon CEO Sheri McCoy discusses her plans for updating the direct seller’s products and streamlining its overall business.

You may also be interested in...



CEO McCoy: Avon Q3 “Disappointing,” But Focus Is On Future

After posting third-quarter profits of $31.6 million, down 81%, Avon announces a cost savings plan aimed at saving the firm $400 million over three years. CEO Sheri McCoy was upbeat about Avon’s prospects, but acknowledged that financial troubles would not be resolved by “a magic bullet or quick fix.”

Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.

Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD

A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018909

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel